MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about board meeting

28 Dec 2017 Evaluate

Pursuant to clause 33 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015, Glaxosmithkline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Friday, 2nd February, 2018, to consider and approve Un-Audited Financial Results for the third quarter and nine months ended 31st December, 2017.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..